Phase-specific cancer-immune model considering acquired resistance to therapeutic agents
From MaRDI portal
Publication:2661016
DOI10.1016/j.amc.2020.125555zbMath1471.92147OpenAlexW3087668731MaRDI QIDQ2661016
Publication date: 1 April 2021
Published in: Applied Mathematics and Computation (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.amc.2020.125555
immunotherapyage-structured modelpharmacokinetics and pharmacodynamics (PKPD)cancer phase-specific modelcancer-immune modelresistance to cancer treatment
Medical applications (general) (92C50) Qualitative investigation and simulation of ordinary differential equation models (34C60)
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- A distribution-free approach to inducing rank correlation among input variables
- Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
- Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics. Homogeneous and heterogeneous approaches
- Modeling immunotherapy of the tumor -- immune interaction
- Models of transcription factor binding: sensitivity of activation functions to model assumptions
- A fractional-order infectivity SIR model
- A methodology for performing global uncertainty and sensitivity analysis in systems biology
- A deterministic and stochastic model for the system dynamics of tumor-immune responses to chemotherapy
- Mathematical modeling of the receptor-mediated endocytosis process of targeted therapeutic agents in drug delivery systems
- Generalizations of the `linear chain trick': incorporating more flexible dwell time distributions into mean field ODE models
- Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: mathematical modeling and dynamical perspective
- Stability analysis of a mathematical model for glioma-immune interaction under optimal therapy
- A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach
- The influence of time delay in a chaotic cancer model
- Sensitivity Analysis in Practice
- A STRATEGY OF OPTIMAL EFFICACY OF T11 TARGET STRUCTURE IN THE TREATMENT OF BRAIN TUMOR
This page was built for publication: Phase-specific cancer-immune model considering acquired resistance to therapeutic agents
